The peptides market is worth $14.1Bn and is growing at an average CAGR of 8.7%. The market is forcasted to grow to $25.5Bn at the end of 2018. The market will grow due to the explosion of non communicable diseases such as metabolic and cardiovascular diseases that that have become endemic in our society.
Peptide technology has been growing at an impressive rate with enhancements in synthesis mechanisms such as solid and liquid phase synthesis. There has also been an impressive growth in the cancer peptide market with a CAGR of 9.4%. Currently the peptide market makes up only 1.55% of the overall market, but this is expected to change thanks to new technologies and the increased number of peptides in the pipeline with 120 in the clinical trial phase and 600 in the preclinical stage.
SMi proudly present their 2nd Annual conference on Peptides taking place on 8th & 9th July 2015 in London. The conference sets the stage for attendees to gain valuable insight into innovative topics such as Cyclic Peptides: R&D platforms, manufacture and stability, Oral Delivery of peptides, Cell permeable peptide therapeutics for cancer treatments and Development of Peptides for the Clinic. Along with this, the programme will provide insight into Formulating Solutions for Delivery and round table discussions on case studies demonstrating the translation of R&D peptides to the clinic.
Electronic Access - Single User Fulfilled By Publisher
CD-ROM Mail Delivery
Electronic Access - Global site License Fulfilled By Publisher